We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Neurimmune Therapeutics Announces Advancement of Alzheimer’s Program into Preclinical Development
News

Neurimmune Therapeutics Announces Advancement of Alzheimer’s Program into Preclinical Development

Neurimmune Therapeutics Announces Advancement of Alzheimer’s Program into Preclinical Development
News

Neurimmune Therapeutics Announces Advancement of Alzheimer’s Program into Preclinical Development

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Neurimmune Therapeutics Announces Advancement of Alzheimer’s Program into Preclinical Development"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Neurimmune Therapeutics AG has announced that, following the successful completion of key research milestones, its lead human therapeutic antibody for Alzheimer’s disease has advanced into preclinical development, triggering milestone payments of an undisclosed amount from Biogen Idec.

Neurimmune partnered with Biogen Idec for the worldwide development and commercialization of novel, fully human antibodies for the treatment of Alzheimer’s disease in November 2007. The alliance focuses on the development of antibodies that bind to amyloid beta (Abeta), a pathogenic molecule thought to cause neurodegeneration and loss of cognitive function in Alzheimer’s patients.

”Neurimmune’s unique Reverse Translational Medicine (RTM™) technology platform combined with in-depth expertise in neuroscience played a critical role in moving the program forward. The fact that we could reach all preclinical milestones in such a short period of time shows that our RTM™ technology can significantly accelerate the transition from discovery to development of human monoclonal antibodies,” said Jan Grimm, Chief Scientific Officer of Neurimmune Therapeutics.

“The rapid advancement into preclinical development demonstrates the progress and productivity of our collaboration with Biogen Idec – we are very happy to work with a partner that has such extensive and valuable experience in the development of biopharmaceuticals. The significant milestone payments also provide Neurimmune with additional financial stability to support the sustainable future development of our company,” said Michael Salzmann, COO and General Manager of Neurimmune Therapeutics.
Advertisement